Compare FMC Corp (FMC) vs Johnson Controls International PLC (JCI) Price & Performance

FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.

The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.

JCI trades at $139.67, down 3.84% on the day, with a bullish technical signal from moving averages and support at $140. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.32. Revenue for 2025 was $23.60B, net income $3.29B, and profit margin expanded to 13.94%. Analyst consensus is strongly bullish with a $158.29 price target and no sell ratings among 45 analysts. Recent news highlights innovation awards and dividend declarations.

JCI presents a favorable outlook with consistent earnings beats, strong analyst support, and exposure to growth areas like energy efficiency. Risks include high valuation multiples (P/E 43.66) and increasing debt-to-asset ratio (26.06% in 2025). The stock's proximity to the $140 support level offers a potential entry point, but macroeconomic headwinds and execution risks in competitive markets warrant caution for investors seeking stable returns.